Aorfix AAA Stent Graft Body with Aorflex Delivery System SG-HBB-31-111-80-20-A12-22Recalls & reported problems
Lombard Medical Limited · Aorfix AAA Stent Graft Body with Aorflex Delivery System · Class 3 · Implant
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 1
- Deaths reported
- 0
- Injuries reported
- 1
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 05055715611572), received between Dec 9, 2015 and Dec 9, 2015 — classified as 1 injury.
The most frequently reported specific device problem is “Malposition of Device” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Malposition of Device1
Patient problems
- Aneurysm1
- Occlusion1
Recent adverse event reports
The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.
InjuryDec 9, 2015Malposition of Device
THE ORIGINAL PROCEDURE WAS PERFORMED ON THE (B)(6) 2015. THE PATIENT UNDERWENT ABDOMINAL EVAR BY THE LEFT APPROACH. THE PHYSICIAN PLACED THE FISHMOUTH TROUGH JUST BELOW THE RIGHT RENAL ARTERY. BECAUSE HE WAS AFRAID THAT THE STENT GRAFT MIGHT COVER THE LOWER LEFT RENAL ARTERY, HE REMOVED THE DELIVERY SYSTEM AND TOUCHED-UP BY BALLOONING UNDER THE CONDITION OF INSERTING AN ANGIOGRAPHIC CATHETER FROM THE RIGHT BRACHIAL ARTERY. BOTH THE RIGHT AND LEFT RENAL ARTERIES IMAGES WERE REVEALED AT THE FINAL ANGIOGRAPHY. THE PROCEDURE WAS FINISHED. ON THE (B)(6) 2015, THE POST-OPERATIVE CT REVEALED THAT THE STENT GRAFT WAS COVERING THE RIGHT RENAL ARTERY AND AS A RESULT, IT WAS OCCLUDED. PATIENT'S CONDITION: RENAL FUNCTION DETERIORATION, CREATININE LEVEL 1.3 MG/DL. THE PATIENT WILL BE FOLLOWED UP AS PER STANDARD PROCEDURES.
Patient problems: Aneurysm; Occlusion
MAUDE report 5278420 ↗
Other System, Endovascular Graft, Aortic Aneurysm Treatment devices
- Endurant® IIs ESBF2814C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls34 deaths254 reports
- Endurant® IIs ESBF3214C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls19 deaths173 reports
- Endurant® IIs ESBF3614C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT1 recall37 deaths214 reports
- Endurant® IIs ESBF2514C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls18 deaths136 reports
- Endurant® IIs ESBF2314C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls9 deaths60 reports
- RelayPro Thoracic Stent-Graft System 28-N4-34-154-34UBolton Medical Inc. · System, Endovascular Graft, Aortic Aneurysm Treatment3 recalls7 reports
- Vela Proximal Endograft System A34-34/C100-O20 VEndologix LLC · System, Endovascular Graft, Aortic Aneurysm Treatment3 deaths152 reports
- Endurant® II ETCF2828C49EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls7 deaths44 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page